What Was Approved?
On June 11, 2025, the U.S. Food and Drug Administration approved Ibtrozi (taletrectinib) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer, or NSCLC.
Patients should be selected for treatment based on the presence of a qualifying ROS1 rearrangement in the tumor.
How Does Ibtrozi Work?
Ibtrozi is a ROS1 kinase inhibitor.
It is designed to block abnormal ROS1 signaling that can promote cancer-cell growth in certain NSCLC tumors.
How Is Ibtrozi Taken?
The recommended dose is:
600 mg by mouth once daily on an empty stomach.
Patients should avoid food for at least 2 hours before and 2 hours after taking the dose.
What Did the Clinical Trials Show?
FDA approval was supported by the TRUST-I and TRUST-II trials.
Among patients who had not previously received a ROS1 tyrosine kinase inhibitor, the overall response rate was high, and responses were also observed in patients previously treated with one ROS1 inhibitor.
These results describe the study populations and do not guarantee the same response for every patient.
What Monitoring Is Important?
The FDA label recommends evaluation of:
- Liver function
- Electrolytes
- ECG
- Uric acid
before starting treatment.
Bottom Line
Ibtrozi (taletrectinib) is an FDA-approved oral targeted therapy for adults with locally advanced or metastatic ROS1-positive NSCLC.
Treatment requires appropriate tumor testing and oncology monitoring.
Sources
- U.S. Food and Drug Administration (FDA) — FDA Approves Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer, June 11, 2025.
- U.S. Food and Drug Administration (FDA) — Drug Trials Snapshot: Ibtrozi.
- U.S. Food and Drug Administration (FDA) — Ibtrozi Prescribing Information, 2025.